New hope for Tough-to-Treat lymphoma patients
NCT ID NCT05716087
Summary
This study is testing an oral medication called rocbrutinib for people with mantle cell lymphoma whose cancer has returned or stopped responding to previous treatments, including other similar drugs. About 62 participants will take the medication to see how well it shrinks tumors and how safe it is. The goal is to find a new treatment option for patients who have run out of effective therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated hospital of hebei university
Baoding, China
-
Anhui provincial cancer hospital
Hefei, Anhui, China
-
Beijing Boren Hospital
Beijing, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship hospital
Beijing, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
-
Fujian Medical university union hospital
Fuzhou, Fujian, China
-
Gansu provincial cancer hospital
Lanzhou, Gansu, China
-
Harbin First Hospital
Harbin, Heilongjiang, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Henan provincial people's hospital
Zhengzhou, Henan, China
-
Hubei Cancer Hospital
Wuhan, China
-
Hunan cancer hospital
Changsha, Hunan, China
-
Jiangsu cancer hospital
Nanjing, Jiangsu, China
-
Jiangsu province hospital
Nanjing, Jiangsu, China
-
Meizhou people'shospital
Meizhou, Guangdong, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100089, China
-
Qilu hospital of Shandong university
Jinan, Shandong, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Shengjing hospital of China medical university
Shenyang, Liaoning, China
-
Sichuan Cancer Hospital
Chengdu, China
-
Sun Yat-sen Memorial Hospital
Guangzhou, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
-
The First Affiliated Hospital of Soochow University
Suzhou, China
-
The First Bethune Hospital of Jilin University
Changchun, China
-
The First People's Hospital of Foshan
Foshan, China
-
The first affiliated hospital of Anhui medical university
Hefei, Anhui, China
-
The first affiliated hospital of Chongqing mediacal university
Chongqing, Chongqing Municipality, China
-
The first affiliated hospital of Nanchang university
Nanchang, Jiangxi, China
-
The first affiliated hospital of Wenzhou medical university
Wenzhou, China
-
The first affiliated hospital of Xiamen university
Xiamen, Fujian, China
-
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, China
-
The first hospital of China medical university
Shenyang, Liaoning, China
-
The fourth hospital of Hebei medical university
Shijiazhuang, Hebei, China
-
The second hospital of dalian medical university
Dalian, Liaoning, China
-
Tianjin Hematonosis Hospital
Tianjin, Tianjin Municipality, China
-
Tianjin medical university cancer hospital
Tianjin, Tianjin Municipality, China
-
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
-
West China School of Medicine
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.